The Impact of Race on Survival and Treatment in Veterans Treated for Metastatic Castration-Resistant Prostate Cancer
Journal of the National Comprehensive Cancer Network · 2025
DOI: 10.6004/jnccn.2025.7078 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Journal of the National Comprehensive Cancer Network, 2025. Verfasst von Danielle Candelieri-Surette und 7 weiteren Autor:innen. Beteiligte Einrichtung: 1University of Massachusetts Lowell, Lowell, MA. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, Veterans. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 116 Literaturangaben.
Abstract (Originalsprache)
Background
Black individuals have higher incidence and mortality rates of prostate cancer than White individuals, and existing literature on treatment sequencing strategies in metastatic castration-resistant prostate cancer (mCRPC) is limited and conflicting. Understanding the interplay between race and treatment could optimize care and improve overall survival (OS).
Methods
This retrospective observational cohort study assessed survival outcomes based on race and initial androgen receptor pathway inhibitor (ARPI) treatment among veterans with mCRPC. Participants included White or Black veterans diagnosed with mCRPC between January 1, 2011, and March 12, 2024, initially treated with either abiraterone or enzalutamide. The primary outcome was OS measured from the date of diagnosis and from the start of initial therapy. Kaplan-Meier estimates and Cox proportional hazards models were used to evaluate outcome differences by race and treatment.
Results
A total of 12,355 patients met eligibility criteria. The mean age of the cohort was 74.57 years, with Black patients diagnosed approximately 4 years younger than White patients (71.77 vs 75.60, respectively; P
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- 1University of Massachusetts Lowell, Lowell, MA.
- 2VA Informatics and Computing Infrastructure, VA Salt Lake City Health Care System, Salt Lake City, UT.
- 3Medicine Service, St. Louis Veterans Affairs Health Care System, St. Louis, MO.
- 4Division of Hematology/Oncology, Department of Internal Medicine, Saint Louis University School of Medicine, St. Louis, MO.
- 5Division of Epidemiology, Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, UT.
- 6Center for Healthcare Organization and Implementation Research, Department of Veterans Affairs, Bedford Healthcare System, Bedford, MA.
Zitieren
APA
Candelieri-Surette, D., Cheranda, N., Lee, J., Teerlink, C. C., Pimentel, C., Lynch, J. A., Berlowitz, D., & Schoen, M. W. (2025). The Impact of Race on Survival and Treatment in Veterans Treated for Metastatic Castration-Resistant Prostate Cancer. Journal of the National Comprehensive Cancer Network. https://doi.org/10.6004/jnccn.2025.7078
Vancouver
Candelieri-Surette D, Cheranda N, Lee J, Teerlink CC, Pimentel C, Lynch JA, et al. The Impact of Race on Survival and Treatment in Veterans Treated for Metastatic Castration-Resistant Prostate Cancer. Journal of the National Comprehensive Cancer Network. 2025. doi:10.6004/jnccn.2025.7078
BibTeX
@article{CandelieriSurette2025,
author = {Candelieri-Surette, Danielle and Cheranda, Nina and Lee, JongSoo and Teerlink, Craig C and Pimentel, Camilla and Lynch, Julie A and Berlowitz, Dan and Schoen, Martin W},
title = {The Impact of Race on Survival and Treatment in Veterans Treated for Metastatic Castration-Resistant Prostate Cancer},
journal = {Journal of the National Comprehensive Cancer Network},
year = {2025},
doi = {10.6004/jnccn.2025.7078}
}
EUVIMED